Geron appointed Dr. Lawlis to its board of directors. He has 30 years experience in theraputic development and manufacturing. He will be used in the two innovative, first-in-class oncology product candidates, imetelstat and GRN1005. Hoping for good results at the end of this year on 4 Phase two trials.
Geron was down 1 cent on only 874,869 shares closing at $1.71.
If you're interested in any of the ads please click.
Good luck in this rigged casino,
No comments:
Post a Comment